Sana Biotechnology, Inc.
sana.comWhat Do They Do?
Develops cell therapies to replace or repair cells in patients, including pancreatic islet-cell treatments for diabetes and therapies that engineer immune cells to target B cell cancers and autoimmune diseases.
10-K for FY2025, filed Mar 3, 2026We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several…View ↗
For our ex vivo platform, we have made focused investments in our hypoimmune platform technology, which we refer to as our HIP technology…View ↗
We are currently focused on advancing two distinct therapeutics, each of which leverages one of these platform technologies. SC451 is our…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 3, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$63.6MView ↗
- ▼ −32% (Loss)
- vs −$93.8M in Q2 FY2025
Narrower program focus
The earlier report described a broad pipeline across cancer, diabetes, central nervous system and genetic disorders, including allogeneic CAR T therapies. The latest report centers on a hypoimmune islet-cell therapy for diabetes and an in vivo CAR T therapy for B cell diseases, and says development of allogeneic CAR T programs is suspended.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 3, 2026We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several…View ↗
We are currently focused on advancing two distinct therapeutics, each of which leverages one of these platform technologies. SC451 is our…View ↗
Previously, we were also pursuing programs in the field of HIP-edited ex vivo CAR T therapy. However, in order to prioritize development of…View ↗
Who Do They Compete With?
Competes with AbbVie, Allogene Therapeutics, Aspect Biosystems, AstraZeneca, Bristol-Myers Squibb, Cabaletta Bio, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Eli Lilly and, Gilead Sciences, Johnson & Johnson, Kelonia Therapeutics, Kyverna Therapeutics, Legend Biotech, Novartis, Roche Holding, Umoja Biopharma, and Vertex Pharmaceuticals
10-K for FY2025, filed Mar 3, 2026Other companies have stated that they are developing cell and gene therapies that may address type 1 diabetes, oncology, and B cell…View ↗
Loading...
